ストックスクリーナーアプリを入手
2.40
0.84%
0.02
アフターアワーズ：
2.47
0.07
+2.92%
前日終値:
$2.38
開ける：
$2.4
24時間の取引高:
1.12M
Relative Volume:
0.46
時価総額：
$56.60M
収益：
$155.00K
当期純損益:
$-30.01M
株価収益率:
-1.4371
EPS:
-1.67
ネットキャッシュフロー:
$-11.98M
1週間 パフォーマンス:
+15.94%
1か月 パフォーマンス:
-62.38%
6か月 パフォーマンス:
-68.71%
1年 パフォーマンス:
-71.90%
1日の値動き範囲:
$2.31
$2.44
1週間の範囲:
$2.05
$2.48
52週間の値動き範囲:
$1.89
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
名前
Inmune Bio Inc
セクター
電話
(858) 964-3720
住所
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
INMB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.40 | 56.39M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-01 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-01 | ダウングレード | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-21 | 開始されました | Alliance Global Partners | Buy |
| 2024-09-27 | 開始されました | Raymond James | Outperform |
| 2024-08-22 | 開始されました | Scotiabank | Sector Outperform |
| 2023-06-01 | 開始されました | Robert W. Baird | Outperform |
| 2022-05-24 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
| 2021-04-21 | 開始されました | B. Riley Securities | Buy |
| 2021-01-22 | 繰り返されました | Maxim Group | Buy |
| 2020-09-01 | 開始されました | BTIG Research | Buy |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Inmune Bio Inc (INMB) 最新ニュース
When (INMB) Moves Investors should Listen - news.stocktradersdaily.com
What analysts say about INmune Bio Inc. stockUnprecedented market success - jammulinksnews.com
INmune Bio Inc. Stock Analysis and ForecastUnbelievable profit margins - jammulinksnews.com
What drives INmune Bio Inc. stock priceRapid wealth accumulation - jammulinksnews.com
Is INmune Bio Inc. a good long term investmentRapid wealth accumulation - Autocar Professional
Is INmune Bio Inc. stock overhyped or has real potentialFree Stock Selection with 300% Return - Newser
Why INmune Bio Inc. stock attracts strong analyst attentionInsider Strategy Insight - Newser
How INmune Bio Inc. stock performs during market volatilityCapital Growth Picks - Newser
Cambridge Investment Research Advisors Inc. Makes New $180,000 Investment in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
What makes INmune Bio Inc. stock price move sharplyTop Momentum Stock Pick - Newser
INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN
Where are the Opportunities in (INMB) - news.stocktradersdaily.com
INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints - MSN
INmune Bio reverses early gains after stock offering - MSN
INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug - MSN
INmune Bio's Alzheimer's drug misses mid-stage goal, shares sink to record low - MSN
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Benzinga
INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble - MSN
XPro™'s Subgroup Success: A Silver Lining in INmune Bio's Alzheimer's Setback - AInvest
INmune Bio's $19M Funding: A Lifeline or a Launchpad for Breakthroughs? - AInvest
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
(INMB) Proactive Strategies - news.stocktradersdaily.com
INmune Bio Shares Fall After Downgrade From BTIG Research - MarketScreener
INmune Bio Shares Plunge After Alzheimer's Trial Misses Target - Finimize
INmune Bio (INMB) Faces Significant Downgrade by Scotiabank | INMB Stock News - GuruFocus
A Drug-Trial Stock Sale - Bloomberg
INmune Bio stock downgraded by Raymond James after Alzheimer’s trial miss - Investing.com Australia
Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering - Stock Titan
Raymond James Downgrades INmune Bio to Market Perform From Outperform; Shares Fall - MarketScreener
Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s - TipRanks
INmune Bio shares tumble as Alzheimer’s drug falls short in mid-stage trial - Proactive Investors
INmune Bio's XPro: A Missed Milestone or a Hidden Gem in Alzheimer's Drug Development? - AInvest
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial By Stocktwits - Investing.com India
INmune Bio’s Stock Tanks: Worth Considering? - timothysykes.com
INmune Bio’s Alzheimer’s drug shows benefit in inflammatory subset - Investing.com
INmune Bio’s Alzheimer’s drug shows benefit in inflammatory subset By Investing.com - Investing.com UK
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease - The Manila Times
Will INmune Bio Succeed In The Alzheimer's Trial Of XPro? Data To Be Shared June 30, 2025 - Nasdaq
INmune Bio's $19M Financing: A Strategic Move to Fuel Alzheimer's Catalyst and Build Investor Confidence - AInvest
INmune Bio (INMB) Shares Drop 11% Following Equity Offering Announcement - GuruFocus
INmune Bio (INMB) Initiates $19M Direct Stock Offering | INMB Stock News - GuruFocus
INmune Bio, Inc. Announces Approximately $19 Million Registered - GuruFocus
INmune Bio (INMB) Surges 61% on Anticipation of Alzheimer's Drug Data - GuruFocus
INmune Bio (INMB) Plunges 27.68% Amid Equity Offering - AInvest
INmune Bio to present Phase 2 Alzheimer’s trial data on June 30 - Investing.com Nigeria
Inmune Bio Inc (INMB) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
大文字化:
|
ボリューム (24 時間):